Catalyst Biosciences secures Sharpe Ratio (or Efficiency) of -0.061, which signifies that the company had -0.061% of return per unit of risk over the last month. Macroaxis standpoint towards foreseeing the risk of any stock is to look at both systematic and unsystematic factors of the business, including all available market data and
technical indicators. Catalyst Biosciences exposes twenty-eight different
technical indicators, which can help you to evaluate volatility that cannot be
diversified away. Please be advised to confirm Catalyst Biosciences
mean deviation of 2.97, and Risk Adjusted Performance of
(0.08) to double-check the risk estimate we provide.
Typically, a company's
financial statements are the reports that show the
financial position of the company. There are three main documents that fall into the category of financial statements. These documents include Catalyst Biosciences income statement, its balance sheet, and the statement of cash flows. Potential Catalyst Biosciences investors and stakeholders use financial statements to determine how well the company is positioned to perform in the future. Although Catalyst Biosciences investors may use each financial statement separately, they are all related. The changes in Catalyst Biosciences's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Catalyst Biosciences's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. Please read more on our
technical analysis and
fundamental analysis pages.
The goal of Catalyst Biosciences
fundamental analysis is to do accurate financial forecasts. There are several possible objectives to fundamental analysis, such as projecting of Catalyst Biosciences performance into the future periods or doing a reasonable stock valuation. The intrinsic value of Catalyst Biosciences shares is the value that is considered the true value of the share. If
the intrinsic value of Catalyst is higher than its market price, buying is generally recommended. If it is equal to the market price, it is recommended to hold; and if it is less than the market price, then one should sell all shares Catalyst Biosciences. Please read more on our
fundamental analysis page.
And What about dividends?
A dividend is the distribution of a portion of Catalyst Biosciences earnings, decided and managed by the company's board of directors and paid to a class of its shareholders. Note, announcements of dividend payouts are generally accompanied by a proportional increase or decrease in a company's stock price. Catalyst Biosciences dividend payments follow a chronological order of events, and the associated dates are important to determine the shareholders who qualify for receiving the dividend payment. Catalyst one year expected dividend income is about USD0.56 per share.
Investing in stocks that pay
dividends, such as stock of Catalyst Biosciences, is one of many strategies that are good for long-term investments. Ex-dividend dates are significant because investors in Catalyst Biosciences must own a stock before its ex-dividend date to receive its next dividend.
This type of analysis is very useful when you want to generate a past dividend schedule and payout information for Catalyst Biosciences. Then that information in the form of graph and calendar can be used to fully explain how Du Pont dividends can provide a real clue to its valuation.
How important is Catalyst Biosciences's Liquidity
Catalyst Biosciences
financial leverage refers to using borrowed capital as a funding source to finance Catalyst Biosciences ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. Catalyst Biosciences financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to Catalyst Biosciences' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of Catalyst Biosciences' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between Catalyst Biosciences's total debt and its cash.
Breaking down the case for Catalyst Biosciences
Institutional investors typically avoid acquiring a high percentage of Catalyst Biosciences stocks because performing such an act may violate securities laws. They are usually not investing their own money, but rather making investments on behalf of their clients. Let's take a look at how the ownership of Catalyst is distributed among investors.
Ownership Allocation
Catalyst Biosciences retains a total of 22.05 Million outstanding shares. Over half of Catalyst Biosciences outstanding shares are owned by
other corporate entities. These other corporate entities are typically referred to corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Consequently, these
institutions are subject to different rules and regulation than regular investors in Catalyst Biosciences. Please watch out for any change in the
institutional holdings of Catalyst Biosciences as this could mean something significant has changed or about to change at the company. Remember, it does not matter who owns the company or if the company is currently
losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.
| Retail Investors40.42% | Insiders5.59% | Institutions53.99% |
| Retail Investors | 40.42 |
| Insiders | 5.59 |
| Institutions | 53.99 |
Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Catalyst Biosciences has an asset utilization ratio of 23.55 percent. This suggests that the company is making $0.24 for each dollar of assets. An increasing asset utilization means that Catalyst Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.
| Current Assets | 101.07 Million | 97.44 |
| Assets Non Current | 2.55 Million | 2.46 |
| Goodwill | 101,526 | 0.0979 |
Chances of Catalyst Biosciences institutional investors to go insane
The kurtosis is down to 1.51 as of today. Catalyst Biosciences exhibits very low volatility with skewness of -0.28 and kurtosis of 1.51. However, we advise investors to further study Catalyst Biosciences technical indicators to make sure all market info is available and is reliable.
Our Conclusion on Catalyst Biosciences
Whereas some other companies in the biotechnology industry are either recovering or due for a correction, Catalyst may not be as strong as the others in terms of longer-term growth potentials. With a somewhat neutral outlook on your 30 days horizon, it may be better to hold off any trading activity and neither pick up new shares of Catalyst nor exit your existing holdings in the Stock. It seems the expected volatility has not yet been fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Catalyst Biosciences.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of Catalyst Biosciences. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
